Tang Youcai
Department of Pediatrics, The Second Affiliated Hospital, Zhengzhou University, 2 Jingba Road, Zhengzhou, 450014, Henan, China,
Dig Dis Sci. 2015 Jun;60(6):1554-64. doi: 10.1007/s10620-014-3487-6. Epub 2014 Dec 23.
Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease, which is often accompanied by obese and/or type II diabetes mellitus. Approximately one-third of NASH patients develop hepatic fibrosis. Hepatic stellate cells are the major effector cells during liver fibrogenesis. Advanced liver fibrosis usually proceeds to cirrhosis and even hepatocellular carcinoma, leading to liver failure, portal hypertension and even death. Currently, there are no approved agents for treatment and prevention of liver fibrosis in human beings. Curcumin, the principal curcuminoid of turmeric, has been reported to show antitumor, antioxidant, and anti-inflammatory properties both in in vitro and in vivo systems. Accumulating data shows that curcumin plays a critical role in combating liver fibrogenesis. This review will discuss the inhibitory roles of curcumin and update the underlying mechanisms by which curcumin targets in inhibiting hepatic stellate cell activation.
非酒精性脂肪性肝炎（NASH）是非酒精性脂肪肝病的晚期形式，常伴有肥胖和/或II型糖尿病。大约三分之一的NASH患者会发展为肝纤维化。肝星状细胞是肝脏纤维化形成过程中的主要效应细胞。晚期肝纤维化通常会发展为肝硬化甚至肝细胞癌，导致肝衰竭、门静脉高压甚至死亡。目前，尚无获批用于治疗和预防人类肝纤维化的药物。姜黄素是姜黄的主要姜黄素类化合物，据报道在体外和体内系统中均具有抗肿瘤、抗氧化和抗炎特性。越来越多的数据表明，姜黄素在对抗肝脏纤维化形成中起关键作用。本综述将讨论姜黄素的抑制作用，并更新姜黄素靶向抑制肝星状细胞激活的潜在机制。
